Buy Rossari Biotech; target of Rs 1085: Anand Rathi

Anand Rathi's research report on Rossari Biotech

With a diversified product portfolio and a strong balance sheet, we believe Rossari Biotech is well positioned to capitalise on emerging opportunities and drive healthy growth in coming years. We expect it is likely to deliver 18%/22%/25% revenue/EBITDA/PAT CAGRs over FY25-27 due to swelling demand, capacity expansion and mounting exports.

Outlook

We expect a consistently better performance aided by capacity expansion, product launches and better margins. We value the stock at 25x FY27e EPS at a TP of Rs1,085.

For all recommendations report, click here